FFreeCE GuideContinuing education · No cost

Provider profile

Academy for Continued Healthcare Learning: free CE courses

Free ACCME-accredited CME from the Academy for Continued Healthcare Learning. The adapter indexes the featured public homepage activities with individually designated AMA PRA Category 1 credit, no-fee statements and expiration dates; login-required catalog inventory is outside the reviewed scope.

free catalogChecked Oct 10, 2026Free provider account may be required

The provider states that its CME programs are free; each activity must independently verify no participation or certificate fee.

Registration may be required. Credit designation, audience and expiration are activity-specific.

Explore the provider’s catalog ↗
Physicians

Upcoming sessions appear soonest first. Times include the provider’s time zone; on-demand learning is listed separately.

8 courses found

Ready when you are

Available on demand

Academy for Continued Healthcare Learning

Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients

Asparaginase, a cornerstone of regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in pediatric and adult patients, is frequently complicated by a distinct spectrum of toxicities which pose significant clinical management challenges. The management of ALL/LBL in adolescent and young adults (AYA) is particularly complex, and these patients often have reduced survival due to their unique needs, challenges with transitions of care, and divergent management across different providers and settings.To mitigate barriers and improve outcomes in patients with ALL/LBL, this

1 CMEOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

How Should I Treat AChR-Ab Seronegative gMG? Weighing The Latest Evidence to Inform Precision-Based Care

No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Clinicians must integrate factors such as age of onset, autoantibody profile, clinical manifestation, gender, and thymic pathology to classify gMG subtypes and tailor treatment strategies. The treatment armamentarium has also recently expanded with novel agents and expanded indications, further complicating decisions.To help clinicians interpret and apply the growing body of evidence in treatment selection across gMG subtypes, this point-counterpoint digital activity uses case-based di

1.5 CMEOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

Integrating Clinical Pharmacists Into Collaborative Care For Patients With T2D To Realize Early Benefits of Once-Weekly Insulin Regimens

The management of type 2 diabetes (T2D) is complex, requiring a multidisciplinary, patient-centered approach that accounts for individualized glycemic and weight goals, comorbidities, hypoglycemia risk, medication costs, and individual preferences. Therapeutic inertia and patient reluctance often delay insulin initiation and intensification in patients with persistent hyperglycemia despite multiple antihyperglycemic agents. The emergence of once-weekly basal insulin analogues represent a transformative advancement in T2D management, offering a simplified treatment paradigm to address common ba

3.5 ACPE CPEOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs

The management of hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–negative (HER2-negative) metastatic breast cancer (mBC) is undergoing rapid transformation, largely driven by the imperative to overcome acquired endocrine resistance, frequently mediated by somatic estrogen receptor 1 (ESR1) mutations. These mutations predict a lack of benefit from further aromatase inhibitor (AI) therapy, making the correct identification and subsequent targeting of these alterations critical for guiding treatment selection. Next-generation oral selective estrogen receptor deg

2 CME · 2 credit tracksOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

Strategies for Improving ERBB2 (HER2) Testing in NSCLC Within Community Settings

The pace at which targetable tumor-specific molecular alterations have been identified over the past decade have ushered in an era of precision oncology, yielding significant insights into the diversity of cancer, offering diagnostic and prognostic benefits, and guiding therapy selection. Indeed, guidelines emphasize that comprehensive biomarker testing should be conducted to identify actionable mutations in non-small-cell lung cancer (NSCLC), including ALK, EGFR, KRAS, MET, RET, and ERBB2 (HER2). These tests guide the selection of targeted therapies that can inhibit oncogenic pathways directl

2.5 CME · 2 credit tracksOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings

Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings. A free accredited ACHL enduring CME/CE activity.

4.5 CMEOn demandChecked Oct 10, 2026
Fully freeDetails
Available on demand

Academy for Continued Healthcare Learning

Unlocking the Therapeutic Potential of Amylin-Based Therapies for Obesity

Obesity is a chronic, progressive, and relapsing disease that imposes a substantial clinical burden. Despite the availability of approved pharmacologic agents with varying mechanisms of action, efficacy, tolerability, and accessibility, only a small percentage of eligible patients are prescribed evidence-based medications, often due to clinician knowledge gaps, concerns regarding long-term safety, and a persistent but inaccurate perception of obesity as a failure of willpower rather than a multifactorial neuroendocrine disorder. Clinicians also encounter significant limitations with available

1 CMEOn demandChecked Oct 10, 2026
Fully freeDetails

Know before you choose

Choosing free courses from Academy for Continued Healthcare Learning

0upcoming sessionsNearest start time first →8on-demand coursesLearn on your schedule →
8fully free coursesNo reporting fee identified in these listings

Compare the credits in this collection

Amounts below are per course and per credit type. Different units and alternative tracks are not added together.

Credit typeRecorded amountCourses
ACPE CPEcontact hour2–3.5 contact hours3
CMEcredit1–4.5 credits7
Nursing CEcontact hour1.25 contact hours1

Choosing the right course

Are the course and certificate both free?

This collection contains 8 current courses with no separate reporting fee identified. Every included course has $0 learning, assessment and certificate costs. A provider may also sell other courses; the whole external catalog is not assumed to be free.

How do I check credit eligibility?

Match the credit type and listed role on the individual course page to your credential. Credit counts here include only the recorded tracks. A listed accrediting body or provider does not establish acceptance by every state board. Review the course approval notes and your board’s rules.

Should I choose an upcoming session or an older recording?

0 scheduled sessions are coming up; 8 courses are currently on demand. Choose an upcoming session if its date and time zone suit you, or on-demand learning for flexibility. A recording’s age alone does not determine credit eligibility. Expired and withdrawn listings are kept in Past & unavailable.

Primary sources